Business Wire
-
Fabric Genomics Partners With Intermountain Children’s Health To Enhance Precision Diagnosis Of Infants And Children Using Whole Genome Sequencing From Broad Clinical Labs
3/13/2024
Fabric Genomics, the leader in artificial intelligence (AI)-powered next generation sequencing interpretation, is announcing a new partnership with Intermountain Children’s Health to analyze the whole genomes of children sequenced by the Broad Clinical Labs to help speed diagnosis of kids who may have genetic diseases.
-
Beckman Coulter And Fujirebio Expand Partnership To Develop Patient-Friendly, Blood-Based Neurodegenerative Disease Diagnostics
3/12/2024
Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced an expansion of their partnership focused on development, manufacturing and clinical adoption of neurodegenerative disease assays.
-
Wolters Kluwer Strengthens Clinical GenAI Market Leadership With AI Labs Powered By Uptodate
3/11/2024
Wolters Kluwer Health today announced several key milestones for AI Labs, the Clinical Generative AI (GenAI) beta launched in 2023 and powered by UpToDate, the globally trusted clinical decision support (CDS) solution.
-
QuidelOrtho Receives Health Canada Approval For Quidel Triage PLGF Test For Laboratory Use In Canada
3/6/2024
QuidelOrtho Corporation (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, has received approval from Health Canada for its Triage PLGF test for laboratory use in Canada.
-
New Data Demonstrate Sunbird Bio’s APEX Diagnostic Test Accurately Differentiates Key Alzheimer’s Disease Biomarker In Blood
3/5/2024
Sunbird Bio, a biotechnology company developing proprietary protein- and blood-based technologies to improve diagnosis and treatment of neurological disorders and early-stage cancer, today announced new data demonstrating that their APEX (Amplified Plasmonic EXosomes) amyloid beta (Aβ) test, the company’s investigational blood-based diagnostic in Alzheimer’s disease, effectively discriminated between patients who were positive versus negative for Aβ on positron emission tomography (PET) scans.
-
Bruker Announces Share Purchase Agreement To Acquire Molecular Diagnostics Innovator ELITechGroup
2/28/2024
Bruker Corporation announced today that it has entered into a definitive share purchase agreement with TecFin S.à r.l., a controlled affiliate of PAI Partners, a pre-eminent private equity firm, to acquire ELITechGroup, for €870M in cash, excluding the carved out ELITech clinical chemistry business.
-
Know Labs Announces The KnowU, Its Wearable Non-Invasive Continuous Glucose Monitor
2/27/2024
Know Labs, Inc., an emerging developer of non-invasive medical diagnostic technology, today announced the KnowU, its wearable non-invasive continuous glucose monitor (CGM). The Company announced its first prototype in June 2023.
-
Quanterix Announces First Collaborations With Five Health Networks To Aid The Diagnosis And Clinical Management Of Individuals With Alzheimer’s Disease
2/26/2024
Quanterix Corporation, a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced its first collaborations with health systems in pursuit of their shared goal to improve and simplify Alzheimer’s disease (AD) diagnosis.
-
Naveris Announces Commercial Payor Coverage For NavDx Test From Highmark, Inc.
2/22/2024
Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced that Highmark Inc.
-
Wright State University Foundation, altafiber, Nokia Open 5G Test Lab At Emergence Center One
2/20/2024
The Wright State University Foundation, altafiber, and Nokia are pleased to announce the opening of a 5G Test Lab at Emergence Center One located at 3070 Presidential Drive in Fairborn, Ohio.